Vimarsana
Biggest News Aggregation in the World

Page 2 - Daneng Li News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daneng Li. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daneng Li Today - Breaking & Trending Today

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Vimarsana News

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...

Dr Li on Frontline Treatment Considerations With IO-Based Combinations in Unresectable HCC - Vimarsana News

Dr Li on Frontline Treatment Considerations With IO-Based Combinations in Unresectable HCC

Daneng Li, MD, discusses considerations when choosing between treatment with immuno-oncology-based combination regimens or single-agent TKIs in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma, highlighting which patient and disease factors influence these decisions.

Ongoing Research Could Add to Atezolizumab/Bevacizumab Backbone in First-Line Treatment of Unresectable HCC - Vimarsana News

Ongoing Research Could Add to Atezolizumab/Bevacizumab Backbone in First-Line Treatment of Unresectable HCC

Daneng Li, MD, discusses the current options available for the frontline treatment of patients with unresectable HCC, factors to consider when selecting a treatment regimen for this patient population, how Child-Pugh B score and bleeding could affect these decisions, and ongoing research using the atezolizumab/bevacizumab backbone in novel combinations.

Rapidly Expanding Treatment Armamentarium Improves Outcomes and Instills Hope in Patients With GI Cancers - Vimarsana News

Rapidly Expanding Treatment Armamentarium Improves Outcomes and Instills Hope in Patients With GI Cancers

Daneng Li, MD, highlights the importance of biomarker testing in gastroesophageal and biliary tract cancers, the potential role for targeted therapy in first-line CRC treatment, and when to choose neoadjuvant therapy over upfront surgery and adjuvant therapy in pancreatic cancer.

Dr. Li on the Potential For First-Line Triplet Therapy in HCC - Vimarsana News

Dr. Li on the Potential For First-Line Triplet Therapy in HCC

Daneng Li, MD, discusses the investigation of triplet combination therapy for patients with hepatocellular carcinoma in the phase 1/2 Morpheus-Liver study.